

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY,
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH,
Patent Owner.

Case No. IPR2018-01710
Patent No. 8,586,045

PETITIONER'S SUPPLEMENTAL BRIEF
(REGARDING *FOX FACTORY, INC. v. SRAM, LLC*)

Table of Contents

I. Introduction.....1

II. Legal Standard for Presumption of Nexus2

III. Teva Failed to Meet Its Burden of Establishing that Ajoyv[®] and
Emgality[®] Are Coextensive with the Challenged Claims3

 A. Unclaimed Sequence and Mutations Materially Impact
 Function.....3

 B. Other Unclaimed Features Materially Impact Function5

IV. No Nexus Exists Outside of the Alleged Presumption.....6

GLOSSARY

ADCC	Antibody-dependent cellular cytotoxicity
CDC	Complement-dependent cytotoxicity
CDR	Complementarity-determining region
FDA	U.S. Food and Drug Administration
IPR	<i>Inter partes</i> review
<i>Italicized text</i>	Emphasis added unless otherwise indicated
Lilly or Petitioner	Eli Lilly and Company
pM	picomolar
Teva or Patent Owner	Teva Pharmaceuticals International GmbH
'045 patent	U.S. Patent No. 8,586,045
'614 patent	U.S. Patent No. 9,340,614 (Ex. 1001 in IPR2018-01422)
'951 patent	U.S. Patent No. 9,266,951 (Ex. 1001 in IPR2018-01423)
'881 patent	U.S. Patent No. 9,346,881 (Ex. 1001 in IPR2018-01424)
'794 patent	U.S. Patent No. 8,007,794 (Ex. 2024)

I. Introduction

In *Fox Factory, Inc. v. SRAM, LLC*, the Federal Circuit reaffirmed and clarified that a patentee bears the burden of establishing a presumption of nexus, which requires demonstrating that a product cited for secondary considerations is “coextensive” with the challenged claims. 944 F.3d 1366, 1373 (Fed. Cir. 2019). The court rejected the patentee’s attempt to broaden the coextensiveness requirement to an inquiry of whether the claims “cover” the cited products. *Id.* at 1377.

For nexus in this case, Teva relied solely on the presumption. Sur-reply, 27. Like the patentee in *Fox Factory*, Teva advanced the legally deficient argument that its claims merely “cover[]” Ajovy[®] and Emgality[®]. *Id.*; POR, 55-56; Ex. 2271, ¶127. Teva failed to satisfy the coextensiveness requirement because these products have numerous features that “materially impact” their functionality but are not recited as limitations in the challenged method-of-treatment claims. *Fox Factory*, 944 F.3d at 1375-76. Indeed, the amino acid sequences of Ajovy[®] and Emgality[®] drive their therapeutic properties, i.e., efficacy and safety for treating migraine, which are responsible for Teva’s alleged secondary considerations evidence. All challenged claims, however, broadly recite using antibodies without *any* requirement for sequence and without *any* requirement for particular levels of safety and efficacy, let alone those observed for Ajovy[®] and Emgality[®]. Thus, *Fox Factory* confirms that nexus is lacking.

II. Legal Standard for Presumption of Nexus

Fox Factory reaffirmed that a patentee bears the burden of establishing a presumption of nexus. *Fox Factory*, 944 F.3d at 1373, 1378. If the patentee fails to establish the presumption, the petitioner has no burden of rebuttal. *Id.* at 1375. When a product is covered by multiple patents, the patentee must also show that the secondary considerations are due to the challenged claims, not other patents. *Id.*

Under *Fox Factory*, a patentee relying on the presumption must establish that alleged praise or success is (1) “tied to a specific product” and (2) the product is “coextensive” with the challenged claims. 944 F.3d at 1373. There, the patentee relied on the success of thirteen bicycle chainring products “embody[ing]” the challenged patent. *Id.* at 1370. The court, however, found a lack of coextensiveness because the products’ performance (i.e., improved chain retention) was materially impacted by features not recited as limitations, such as an 80% gap-filling feature that had been specifically claimed in a *different* patent. *Id.* at 1375-76, 1378.

In holding the presumption inapplicable, the court did not require the unclaimed features (e.g., 80% gap-filling) to be specifically identified in industry praise or the sole basis for commercial success. Rather, the presumption did not apply because patentee failed to meet its burden of establishing that those unclaimed features were “insignificant” to the chainring products’ functionality. *Id.* at 1375-76.

Accordingly, *Fox Factory* demonstrates that no presumption of nexus applies

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.